News

Our research in Science Spotlight and Media 

May 18, 2022

Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in EMBO Molecular Medicine

A recent study published in EMBO Mol Med from the Gujral Lab showed N-terminus domain (NTD) of the SARS-CoV-2 Omicron variant spike protien strongly induces multiple inflammatory molecules in peripheral blood mononuclear cells, unaffected by the mutations observed in the NTD. Olverembatinib, a clinical-stage multi-kinase inhibitor, potently inhibits Omicron NTD-mediated cytokine release.

Olverembatinib is a potent inhibitor of Omicron NTD-mediated cytokine release

Olverembatinib is a potent inhibitor of Omicron NTD-mediated cytokine release

APRIL 20, 2022

Development of an in vitro model system to study tricky-to-target tumor microenvironment cells

A recent study published in Cancer Research from the Gujral Lab aimed to develop a physiologically relevant system to study tumor associated macrophages in breast cancer

Tumor-associated macrophages in breast cancer

Tumor-associated macrophages (magenta and green) in breast cancer

DECEMBER 20, 2021

Computational predictions reveal an unexpected synergy for prostate cancer therapy

A recent study published in PNAS from the Gujral Lab  applied machine learning-based functional screening to identify kinase inhibitors that may be effective for CRPC treatment.

3D illustration demonstrating how computational modeling can be used to better understand metastatic prostate cancer.

3D illustration demonstrating how computational modeling can be used to better understand metastatic prostate cancer. 

OCTOBER 18, 2021

New strategy to weather the (cytokine) storm

A recent publication from the laboratory of Dr. Taran Gujral in the Human Biology Division in collaboration with the labs of M. Juliana McElrath (Vaccine and Infectious Disease Division) and Eric Holland (Human Biology) described the identification of a small molecule therapeutic previously approved by the Food and Drug Administration for the treatment of Chronic Myelogenous Leukemia as a potential inhibitor of the tissue damaging cytokine storm.  Their report was published in Molecular Systems Biology.

Machine Learning Identifies Molecular Regulators and Therapeutics for Targeting SARS-CoV-2-induced Cytokine Storm

Machine Learning Identifies Molecular Regulators and Therapeutics for Targeting SARS-CoV-2-induced Cytokine Storm

SEPTEMBER 30, 2021

Using AI to identify potential COVID-19, cancer therapies

Dr. Taran Gujral and teammates demonstrated how machine learning, deep neural networks and other artificial intelligence tools can screen, identify and validate compounds, including some approved drugs, that could provide benefit to patients with advanced prostate cancer and other serious conditions. 

Using AI to identify potential COVID-19, cancer therapies

 Hutch researchers have identified FDA-approved drugs that, in cells and mice, clear this inflammatory response. 

MARCH 04, 2021

Outlining the molecular networks that alter cell function and behavior

Dr. Taran Gujral has received a National Science Foundation CAREER Award to study the molecular networks that govern cells’ ability to make these transitions, with an eye toward designing new ways to intervene in the future.

FEBRUARY 01, 2021

New awards to spur innovation, commercialization in life sciences research

Fred Hutchinson Cancer Research Center and the Washington Research Foundation, or WRF, have announced a new collaborative funding program designed to spur innovative life science and technology research at the Hutch and speed the process of commercialization toward patient impact. 

Dr. Taran Gujral’s NSF CAREER Award will allow him to study how cells shift to new functional states in normal development and disease

Dr. Taran Gujral’s NSF Award will allow him to study how cells shift to new functional states in normal development and disease

Dr. Taran Gujral (standing) and postdoctoral research fellow Dr. Thomas Bello discuss their research in July 2019.

Dr. Taran Gujral (standing) and postdoctoral research fellow Dr. Thomas Bello discuss their research..

DECEMBER 21, 2020

New “cuboids” and microfluidics technology allows for drug testing in intact tissues

In collaboration with the Gujral lab in the Human Biology Division, the Folch lab at the UW Bioengineering Department has developed a microfluidics platform that delivers minuscule amounts of drugs to small tissue biopsies, called “cuboids.” In the microfluidic device, the cuboids flow through microchannels containing dispersed wells that trap the cuboids for culture and multi-drug exposures. 

A microfluidic platform that permits multiple drug testing of uniformly-sized microscale “cuboids” of live tissue with well-preserved microenvironments.

A microfluidic platform that permits multiple drug testing of uniformly-sized microscale “cuboids” of live tissue with well-preserved microenvironments.

AUGUST 17, 2020

Activation of developmental pathways correlates with poor clinical outcomes across cancer types

During embryogenesis, multiple developmental signaling pathways control the biological processes that form and shape cells, tissues, and organs.  In a recently published study, researchers in the Gujral Lab (Human Biology Division) provides an in-depth analysis of how components of developmental signaling pathways correlate with clinical outcomes across major cancer types.

Activation of developmental pathways correlates with poor clinical outcomes across cancer types

Schematic showing overall approach for pan-cancer data analysis process and methodology.

AUGUST 04, 2020

Shifting liver cancer cells away from migratory state could reduce their drug resistance

Whether a liver cancer cell is primed to grow or move affects its ability to resist cancer drugs, according to new work from scientists at Fred Hutchinson Cancer Research Center and the University of Washington. The team identified key molecules that orchestrate these different cell states in hepatocellular carcinoma, or HCC. In lab dishes, experimental compounds that target these molecules can shift drug-resistant HCC cells toward drug sensitivity.

Shifting liver cancer cells away from migratory state could reduce their drug resistance

A microscope image shows mesenchymal hepatocellular carcinoma cells that have lost their specialized functions, acquired the ability to move and become drug resistant. 

JANUARY 20, 2020

Tumor slices as a robust pre-clinical platform

The Gujral lab in the Human Biology Division has established a screening platform using organotypic tumor slice culture

In the media: "Researchers Use Tumor Slices to Understand Microenvironment." AJMC, 2019.

Also: "Exploring Pre-clinical Cancer Models." News-Medical, 2021.

Tumor slices as a robust pre-clinical platform

Tumor slices as a robust pre-clinical platform